secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2023-07-18T23:59:59+00:00
Accession:  0001193125-23-188532
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Novartis discontinues Phase 3 trial of XOMA-licensed NIS793 in pancreatic cancer; continues in colorectal cancer
--------------------------------------------------------------------------------

- Novartis stopped Phase 3 trial (NCT04935359) of NIS793 in first-line metastatic PDAC based on benefit-risk assessment.
- Trial compared NIS793 plus gem/nab-paclitaxel vs placebo plus gem/nab-paclitaxel; no efficacy or safety established.
- Novartis will continue investigating NIS793 in other indications, including a Phase 2 study in colorectal cancer.
- XOMA licensed NIS793 to Novartis in September 2015 under a license agreement previously filed with the SEC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312523188532/0001193125-23-188532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312523188532/d509906d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-188532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer